JPH10504039A - 多発性硬化症のための組成物および治療法 - Google Patents

多発性硬化症のための組成物および治療法

Info

Publication number
JPH10504039A
JPH10504039A JP8514109A JP51410996A JPH10504039A JP H10504039 A JPH10504039 A JP H10504039A JP 8514109 A JP8514109 A JP 8514109A JP 51410996 A JP51410996 A JP 51410996A JP H10504039 A JPH10504039 A JP H10504039A
Authority
JP
Japan
Prior art keywords
mbp
peptide
multiple sclerosis
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8514109A
Other languages
English (en)
Japanese (ja)
Inventor
ドーン スミレク，
マイケル サムソン，
マルコム ゲフター，
デイ−フウエイ フス，
ジア−ドング シ，
グザビエ パリアール，
ブリジツト デボー，
ジヨナサン ロスバード，
ヘンリー フランゼン，
Original Assignee
イミユロジク・フアーマシユーチカル・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミユロジク・フアーマシユーチカル・コーポレーシヨン filed Critical イミユロジク・フアーマシユーチカル・コーポレーシヨン
Publication of JPH10504039A publication Critical patent/JPH10504039A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP8514109A 1994-10-25 1995-10-25 多発性硬化症のための組成物および治療法 Pending JPH10504039A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US08/328,224 1994-10-25
US40422895A 1995-03-15 1995-03-15
US08/404,228 1995-03-15
PCT/US1995/013682 WO1996012737A2 (fr) 1994-10-25 1995-10-25 Compositions et traitement pour la sclerose en plaques

Publications (1)

Publication Number Publication Date
JPH10504039A true JPH10504039A (ja) 1998-04-14

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8514109A Pending JPH10504039A (ja) 1994-10-25 1995-10-25 多発性硬化症のための組成物および治療法

Country Status (15)

Country Link
EP (1) EP0787147A1 (fr)
JP (1) JPH10504039A (fr)
AU (1) AU4278296A (fr)
BR (1) BR9509438A (fr)
CA (1) CA2203629A1 (fr)
CZ (1) CZ122697A3 (fr)
FI (1) FI971750A (fr)
HU (1) HUT77047A (fr)
IL (1) IL115766A0 (fr)
IS (1) IS4466A (fr)
NO (1) NO971900L (fr)
PL (1) PL324091A1 (fr)
SI (1) SI9520118A (fr)
SK (1) SK51297A3 (fr)
WO (1) WO1996012737A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531497A (ja) * 2002-02-01 2005-10-20 アピトープ テクノロジー （ブリストル） リミテッド ミエリン塩基性タンパク質に由来する免疫寛容ペプチド
JP2017036299A (ja) * 2009-11-30 2017-02-16 リポクセン テクノロジーズ リミテッド ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
GB2326642B (en) 1996-03-21 2001-02-07 Imperial College Cryptic peptides and method for their identification
WO1998006861A2 (fr) * 1996-08-15 1998-02-19 Agrivax Incorporated Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
CA2201841C (fr) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Specificite des peptides de la proteine basique anti-myeline et administration de ces peptides aux patients atteints de sclerose en plaques
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CA2330826A1 (fr) * 1998-05-05 1999-11-11 Corixa Corporation Peptides de proteine basique de myeline et utilisations de ceux-ci
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
EP1288226A1 (fr) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification de l'expression des gènes pour les récepteurs type "Toll" destinée à influencer la neurodégénérescence et la neuroprotection de système nerveux central de l'homme
ES2325660T3 (es) 2002-03-27 2009-09-11 Aegera Therapeutics Inc. Oligomeros nucleobasicos de iap no codificantes y usos de los mismos.
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
CA2667637C (fr) 2006-10-31 2021-04-20 East Carolina University Proteines de fusion comprenant une cytokine anti-inflammatoire et un antigene destinees au traitement de troubles immunitaires
WO2010024927A2 (fr) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Traitement des amyloïdoses au moyen de protéines basiques de myéline ou de fragments desdites
WO2010117848A1 (fr) 2009-03-31 2010-10-14 East Carolina University Cytokines et neuroantigènes utilisés dans le traitement de maladies immunitaires
WO2011046462A1 (fr) 2009-10-12 2011-04-21 Angport Limited Composition pour le traitement de la sclérose en plaques
US8956878B2 (en) 2011-03-21 2015-02-17 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (HSPS) and HSP associated complexes (HACS) and their use in diagnosis and therapy
BR112016016153A2 (pt) 2014-01-13 2017-12-12 Berg Llc composições de enolase 1 (eno1) e usos das mesmas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666080B1 (fr) * 1987-06-24 2004-01-21 Brigham & Women's Hospital Traitement de maladies auto-immunitaires par administration orale d'auto-antigènes
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
HUT61487A (en) * 1989-12-20 1993-01-28 Brigham & Womens Hospital Process for producing aerosol pharmaceutical composition comprising autoantigens
EP0594607B1 (fr) * 1990-03-02 1997-08-27 Autoimmune, Inc. Amelioration de la regulation reductrice de maladies autoimmunes par administration orale ou enterale d'autoantigenes
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (fr) * 1991-10-22 2002-03-12 Kenneth G. Warren Specificite pour les peptides synthetiques de la proteine basique anti-myeline presente dans le liquide cephalorachidien de patients atteints de la sclerose en plaques
JPH07501526A (ja) * 1991-11-19 1995-02-16 アナージェン，インコーポレイティド 有害な免疫応答の改善において有用なｍｈｃサブユニット結合体
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
CA2133749A1 (fr) * 1992-04-09 1993-10-28 Howard L. Weiner Suppression de la proliferation de lymphocytes t a l'aide de fragments peptidiques de la proteine de base de la myeline
WO1993025661A1 (fr) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Clones heterogenes de cellules t specifiques contre le peptide proteolipidique 139-151
JPH08500823A (ja) * 1992-08-17 1996-01-30 オートイミューン インク レトロウィルス関連神経疾患のバイスタンダー抑制
AU7725894A (en) * 1993-09-03 1995-03-22 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
EP0720622A1 (fr) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Interaction des recepteurs de lymphocytes t et de l'antigene dans les maladies auto-immunes
AU695883B2 (en) * 1994-04-08 1998-08-27 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines
WO1995027499A1 (fr) * 1994-04-08 1995-10-19 Brigham And Women's Hospital Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i
SI9520059A (en) * 1994-05-10 1997-08-31 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis.
ATE172304T1 (de) * 1994-06-09 1998-10-15 Tno Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531497A (ja) * 2002-02-01 2005-10-20 アピトープ テクノロジー （ブリストル） リミテッド ミエリン塩基性タンパク質に由来する免疫寛容ペプチド
JP2017036299A (ja) * 2009-11-30 2017-02-16 リポクセン テクノロジーズ リミテッド ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法

Also Published As

Publication number Publication date
FI971750A (fi) 1997-06-24
WO1996012737A3 (fr) 1996-10-10
IL115766A0 (en) 1996-01-19
SK51297A3 (en) 1998-03-04
EP0787147A1 (fr) 1997-08-06
SI9520118A (sl) 1998-08-31
BR9509438A (pt) 1997-12-23
WO1996012737A2 (fr) 1996-05-02
PL324091A1 (en) 1998-05-11
IS4466A (is) 1997-04-17
CA2203629A1 (fr) 1996-05-02
AU4278296A (en) 1996-05-15
FI971750A0 (fi) 1997-04-24
HUT77047A (hu) 1998-03-02
CZ122697A3 (en) 1997-09-17
NO971900D0 (no) 1997-04-24
NO971900L (no) 1997-06-25

Similar Documents

Publication Publication Date Title
JPH10504039A (ja) 多発性硬化症のための組成物および治療法
US6036957A (en) Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US7608685B1 (en) Tumor antigen based on products of the tumor suppressor gene WT1
Schall et al. Peptide-based approaches to treat lupus and other autoimmune diseases
JP6063402B2 (ja) Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用
WO1996012737A9 (fr) Compositions et traitement pour la sclerose en plaques
AU2005221712A1 (en) Identification of self and non-self antigens implicated in autoimmune diseases
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
JP2000512277A (ja) ペプチド誘導体
NO337092B1 (no) Aminosyrekopolymerer for suppresjon av autoimmunsykdommer, preparat og enhetsdoseform samt deres anvendelse
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
CN105121463B (zh) 肽
US8999937B2 (en) Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
JP2012527440A (ja) Ｆｖｉｉｉ由来ペプチド
US6355617B1 (en) Peptide derivatives
Rosloniec et al. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models
JP2003507011A (ja) Ｉｌ−１６拮抗剤
JP4065322B2 (ja) 合成ペプチドおよびそれらを含有する医薬組成物
WO1996011700A1 (fr) Utilisation de substances activatrices de la phospholipase a2 pour reduire les neoplasmes chez les mammiferes
JP2001511143A (ja) コラーゲン▲ｉｉ▼に特異的なｔ細胞エピトープを含むペプチド
JPH09503003A (ja) クラスｉｉのアルファ鎖断片による免疫調節
US20040038920A1 (en) Chlamydial peptides and their mimics in demyelinating disease